Company: LENZ
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001815776-25-000056
Chunk: 288

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-07-30
Form: 10-Q
Item: Part I, Item 1
Chunk 288
---
Item 1. Financial Statements.

LENZ THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except for shares and par value)

June 30, 2025December 31, 2024(unaudited)AssetsCurrent assets:Cash and cash equivalents$37,608 $20,158 Marketable securities171,911 188,872 Prepaid expenses and other current assets3,969 2,773 Restricted cash114 114 Total current assets213,602 211,917 Property and equipment, net1,169 651 Operating lease right-of-use asset959 1,338 Other assets1,602 1,398 Total assets$217,332 $215,304 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$2,854 $4,257 Accrued liabilities7,544 6,149 Total current liabilities10,398 10,406 Operating lease liability, net569 814 Total liabilities10,967 11,220 Commitments and contingencies (Note 6)Stockholders' equity:Common stock, par value of $0.00001 per share; 300,000,000 shares authorized; 28,501,715 and 27,531,490 shares issued at June 30, 2025 and December 31, 2024, respectively; and 28,500,122 and 27,518,439 shares outstanding at June 30, 2025 and December 31, 2024, respectively1 1 Additional paid-in capital380,871 348,901 Accumulated deficit(174,545)(145,014)Accumulated other comprehensive income38 196 Total stockholders’ equity206,365 204,084 Total liabilities and stockholders’ equity$217,332 $215,304 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

1

Table of Contents

LENZ THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

(unaudited)

Three Months Ended June 30,Six Months Ended June 30,2025202420252024Revenue:License revenue$5,000 $— $5,000 $— Total revenue5,